Accuray Incorporated would like to make you aware that the National Comprehensive Cancer Network (NCCN) updated its prostate cancer guidelines (NCCN Guidelines Prostate Cancer Version 1.2020) on March 16, 2020. These updated recommendations state that Stereotactic Body Radiation Therapy (SBRT) can be considered a valid treatment option for the following prostate cancer groups:
- Low-risk prostate cancer
- Favorable intermediate-risk prostate cancer
- Unfavorable intermediate-risk prostate cancer
- Favorable high-risk prostate cancer
- Unfavorable high-risk prostate cancer
In addition to the updated recommendations, a table on page 38 of the NCCN guidelines provides examples of different treatment regimens and preferred doses/fractionation by prostate cancer risk group that have shown acceptable efficacy and toxicity.
The NCCN recommendations regarding the use of SBRT for all high-risk prostate cancer patients (favorable and unfavorable) is a culmination of the extensive clinical data that has been published on the benefits of SBRT in this patient population. This updated recommendation continues to reinforce the clinical benefits of utilizing moderate and ultra-hypofractionated radiation treatments for all risk groups of prostate cancer.
We wish to thank those who have contributed data to support the use of SBRT in patients diagnosed with prostate cancer. We are proud to help you offer a safe alternative to your patients.